Pharmacology of Hypolipidemic Drugs

Introduction/Overview

The management of dyslipidemia represents a cornerstone in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Hypolipidemic drugs, also termed lipid-lowering agents, comprise a diverse group of pharmacological interventions designed to modify circulating plasma lipid and lipoprotein concentrations. The clinical imperative for these agents stems from the established causal relationship between elevated levels of low-density lipoprotein cholesterol (LDL-C) and the development of coronary artery disease, cerebrovascular disease, and peripheral arterial disease. Beyond LDL-C, therapeutic strategies also target other atherogenic particles, including triglyceride-rich lipoproteins and lipoprotein(a), as well as aim to elevate cardioprotective high-density lipoprotein cholesterol (HDL-C).

The evolution of hypolipidemic pharmacology reflects an increasing understanding of lipoprotein metabolism, from the early introduction of bile acid sequestrants and fibrates to the revolutionary development of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). Contemporary therapy now includes novel biological agents such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and emerging RNA-targeted therapies. The appropriate selection and use of these agents require a detailed knowledge of their pharmacological properties, efficacy profiles, and safety considerations.

Learning Objectives

• Classify major hypolipidemic drug classes based on their chemical structure and primary mechanism of action.
• Explain the molecular and cellular pharmacodynamics of each drug class, including receptor interactions and effects on lipoprotein metabolic pathways.
• Compare and contrast the pharmacokinetic profiles, including absorption, distribution, metabolism, and excretion, of key agents within each class.
• Evaluate the clinical applications, therapeutic efficacy, and evidence-based indications for each class of hypolipidemic drug.
• Identify major adverse effect profiles, drug interactions, and special population considerations to inform safe and effective prescribing.

Classification

Hypolipidemic drugs are systematically classified according to their primary mechanism of action and chemical structure. This classification provides a framework for understanding their therapeutic roles and pharmacological profiles.

Drug Classes and Categories

• HMG-CoA Reductase Inhibitors (Statins): Atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin.
• Cholesterol Absorption Inhibitors: Ezetimibe.
• Bile Acid Sequestrants (Resins): Cholestyramine, colestipol, colesevelam.
• Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil, bezafibrate.
• PCSK9 Inhibitors: Alirocumab, evolocumab (monoclonal antibodies); inclisiran (small interfering RNA).
• Nicotinic Acid (Niacin): Immediate-release, sustained-release, and extended-release formulations.
• Omega-3 Fatty Acid Preparations: Icosapent ethyl, prescription omega-3-acid ethyl esters.
• Microsomal Triglyceride Transfer Protein (MTP) Inhibitor: Lomitapide.
• Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitor: Bempedoic acid.
• Angiopoietin-like 3 (ANGPTL3) Inhibitors: Evinacumab (monoclonal antibody).

Chemical Classification

From a chemical perspective, these agents are highly heterogeneous. Statins are characterized by a pharmacophore that mimics the HMG-CoA moiety, with structures derived from fungi (lovastatin, simvastatin) or synthesized de novo (atorvastatin, rosuvastatin). Fibrates are analogues of fibric acid, featuring a phenoxyisobutyrate backbone. Bile acid sequestrants are non-absorbable polymeric resins. The biological agents, such as PCSK9 inhibitors, are monoclonal antibodies or oligonucleotides, representing a distinct chemical and therapeutic class.

Mechanism of Action

The pharmacodynamic effects of hypolipidemic drugs are mediated through diverse molecular pathways that influence lipoprotein synthesis, catabolism, and clearance.

HMG-CoA Reductase Inhibitors (Statins)

Statins competitively inhibit HMG-CoA reductase, the enzyme catalyzing the conversion of HMG-CoA to mevalonate, which is the rate-limiting step in hepatic cholesterol biosynthesis. This inhibition results in several compensatory effects. Depletion of intrahepatic cholesterol upregulates the expression of hepatic LDL receptors (LDLR) on the hepatocyte surface. Increased LDLR activity enhances the clearance of LDL and its precursor, intermediate-density lipoprotein (IDL), from the circulation via receptor-mediated endocytosis. Beyond LDL-C reduction, statins exert pleiotropic effects that may contribute to their cardiovascular benefit, including improvement of endothelial function, stabilization of atherosclerotic plaques, and anti-inflammatory and anti-thrombotic properties.

Cholesterol Absorption Inhibitors

Ezetimibe acts locally at the brush border of the small intestine by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein. This protein is responsible for the intestinal absorption of dietary and biliary cholesterol. By blocking this transporter, ezetimibe reduces the delivery of cholesterol to the liver, leading to a depletion of hepatic cholesterol stores. This depletion subsequently triggers an increase in hepatic LDL receptor expression, mirroring the final common pathway of statins, albeit through a different initial mechanism. The combined effect is a reduction in circulating LDL-C.

Bile Acid Sequestrants

These non-absorbable anion-exchange resins bind bile acids within the intestinal lumen, forming an insoluble complex that is excreted in the feces. This interruption of the enterohepatic circulation of bile acids depletes the hepatic bile acid pool. The liver compensates by converting more cholesterol into bile acids, utilizing cholesterol from intracellular stores. The resultant decrease in hepatic cholesterol content stimulates the upregulation of LDL receptor synthesis and activity, thereby increasing the catabolism of plasma LDL. These agents may also cause a modest increase in HDL-C and have been shown to improve glycemic control.

Fibric Acid Derivatives (Fibrates)

Fibrates act as agonists for the peroxisome proliferator-activated receptor-alpha (PPAR-α), a nuclear transcription factor. Activation of PPAR-α alters the expression of numerous genes involved in lipid metabolism. Key effects include: stimulation of lipoprotein lipase (LPL) expression, enhancing the lipolysis of triglyceride-rich lipoproteins (chylomicrons and VLDL); reduction in hepatic apolipoprotein C-III (apo C-III) production, an inhibitor of LPL; and increased hepatic fatty acid β-oxidation, reducing the substrate available for VLDL synthesis. The net results are a significant reduction in plasma triglycerides (30-50%), a moderate increase in HDL-C (5-20%), and a variable, often modest, reduction in LDL-C.

PCSK9 Inhibitors

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that binds to hepatic LDL receptors, promoting their lysosomal degradation and preventing their recycling to the hepatocyte surface. Monoclonal antibodies such as alirocumab and evolocumab bind circulating PCSK9 with high affinity, preventing its interaction with the LDLR. This inhibition allows for greater recycling and surface expression of LDLRs, dramatically enhancing the clearance of LDL particles from plasma. Inclisiran, a small interfering RNA (siRNA), acts at an earlier stage by inducing RNA interference, leading to the degradation of PCSK9 mRNA and a sustained reduction in PCSK9 protein synthesis.

Nicotinic Acid (Niacin)

The lipid-modifying effects of niacin are complex and not fully elucidated. It is known to inhibit hormone-sensitive lipase in adipose tissue, reducing the mobilization of free fatty acids to the liver, which in turn decreases the hepatic synthesis and secretion of VLDL. As VLDL is the precursor to LDL, LDL-C levels fall. Niacin also appears to directly inhibit hepatic diacylglycerol acyltransferase 2, a key enzyme in triglyceride synthesis. Furthermore, it reduces the hepatic clearance of apolipoprotein A-I (apo A-I), increasing the residence time of HDL particles and potentially enhancing reverse cholesterol transport. Its most distinctive effect is a pronounced elevation in HDL-C.

Omega-3 Fatty Acid Preparations

The mechanisms of prescription omega-3 formulations are multifaceted. They incorporate into cell membranes and serve as substrates for the synthesis of less inflammatory eicosanoids. They may also act as ligands for transcription factors like PPARs. Icosapent ethyl, the ethyl ester of eicosapentaenoic acid (EPA), has demonstrated cardiovascular benefit independent of triglyceride lowering, with proposed mechanisms including reduced inflammation, improved endothelial function, and decreased oxidative stress. Omega-3 acids reduce hepatic VLDL-triglyceride synthesis and secretion and enhance triglyceride clearance from plasma.

Pharmacokinetics

The pharmacokinetic properties of hypolipidemic drugs significantly influence their dosing regimens, potential for interactions, and use in special populations.

Absorption

Absorption characteristics vary widely. Most statins are well absorbed orally, but they undergo extensive first-pass metabolism, resulting in low systemic bioavailability (5-30%). The absorption of bile acid sequestrants is negligible as they are not absorbed from the gastrointestinal tract. Ezetimibe is absorbed and extensively conjugated to an active glucuronide metabolite in the intestinal wall and liver. Fibrates are generally well absorbed. The monoclonal antibody PCSK9 inhibitors are administered via subcutaneous injection, with bioavailability ranging from 70-85%. Niacin is rapidly absorbed, but its use is limited by acute vasodilatory side effects linked to its absorption kinetics.

Distribution

Distribution is largely influenced by lipophilicity and plasma protein binding. Lipophilic statins (simvastatin, lovastatin, atorvastatin) distribute widely into extrahepatic tissues, whereas hydrophilic statins (pravastatin, rosuvastatin) have more selective hepatic uptake via organic anion transporter proteins. Most statins are highly bound to plasma proteins (>90%). Ezetimibe and its metabolite are >90% bound to plasma proteins. Monoclonal antibodies distribute primarily within the plasma and extracellular fluid volumes. Fibrates are highly protein-bound, primarily to albumin.

Metabolism

Metabolism is a critical determinant of drug interaction potential. Most statins are metabolized by the cytochrome P450 system. Simvastatin, lovastatin, and atorvastatin are primarily metabolized by CYP3A4. Fluvastatin is metabolized mainly by CYP2C9, and rosuvastatin undergoes limited CYP2C9 metabolism. Pravastatin and pitavastatin are not significantly metabolized by CYPs. Ezetimibe is glucuronidated (UGT enzymes) and undergoes enterohepatic recirculation. Fibrates are metabolized via glucuronidation and oxidation. The monoclonal antibodies are degraded via proteolytic catabolism throughout the body, not by hepatic enzymes.

Excretion

Excretion pathways influence use in renal or hepatic impairment. Statins and their metabolites are primarily excreted in the bile and feces, with renal excretion playing a minor role for most, except for pravastatin and rosuvastatin which have more significant renal elimination. Ezetimibe and its glucuronide are excreted predominantly in the feces (78%) and urine (11%). Bile acid sequestrants and the non-absorbed component of ezetimibe are excreted unchanged in the feces. Fibrates are excreted mainly in the urine as glucuronide conjugates. Monoclonal antibodies are expected to be metabolized to small peptides and amino acids which are recycled or excreted renally.

Half-life and Dosing Considerations

Half-lives range from short (niacin, ~1 hour) to very long (some monoclonal antibodies, 1-4 weeks). Atorvastatin and rosuvastatin have longer half-lives (14-19 hours and 19 hours, respectively), allowing for once-daily dosing at any time. Simvastatin and lovastatin have shorter half-lives (2-3 hours) and are typically dosed in the evening to coincide with peak endogenous cholesterol synthesis. PCSK9 monoclonal antibodies are administered every 2 or 4 weeks due to their prolonged half-life, while inclisiran, with its siRNA mechanism, is dosed twice-yearly after initial loading doses. Dosing of agents like fibrates and bile acid sequestrants must account for food interactions and gastrointestinal tolerability.

Therapeutic Uses/Clinical Applications

The clinical application of hypolipidemic drugs is guided by the specific lipid abnormality, the patient’s absolute cardiovascular risk, and the evidence base for cardiovascular outcomes reduction.

Approved Indications

Statins are first-line therapy for primary and secondary prevention of ASCVD. High-intensity statin therapy (e.g., atorvastatin 40-80 mg, rosuvastatin 20-40 mg) is recommended for most patients with established ASCVD and for those with severe hypercholesterolemia (LDL-C ≥190 mg/dL). Moderate-intensity statins are used for lower-risk primary prevention. Ezetimibe is indicated as adjunctive therapy to statins when additional LDL-C lowering is required, or as monotherapy in statin-intolerant patients. PCSK9 inhibitors are reserved for patients with familial hypercholesterolemia or clinical ASCVD who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe therapy.

Fibrates are primarily indicated for the treatment of severe hypertriglyceridemia (triglycerides ≥500 mg/dL) to prevent pancreatitis. Their role in reducing cardiovascular events in mixed dyslipidemia is more modest and less certain than that of statins. Icosapent ethyl is uniquely approved to reduce cardiovascular events in patients with established ASCVD or diabetes with other risk factors, who have elevated triglycerides (≥150 mg/dL) despite statin therapy. Bile acid sequestrants are used as adjuncts for LDL-C lowering and also have an indication to improve glycemic control in type 2 diabetes. Niacin use has declined markedly due to the lack of incremental cardiovascular benefit on top of statin therapy and a significant adverse effect profile.

Off-label Uses

Certain applications, while not formal indications, are supported by clinical practice guidelines or emerging evidence. Ezetimibe is sometimes used in combination with bile acid sequestrants. Fibrates may be considered in patients with low HDL-C and high triglycerides, though clinical outcome benefits are less clear. The use of PCSK9 inhibitors is sometimes extended to very high-risk patients not meeting strict trial criteria but with progressive disease. Omega-3 fatty acids are frequently used for milder hypertriglyceridemia, though the prescription-strength EPA-only formulation (icosapent ethyl) has the strongest outcomes data.

Adverse Effects

The tolerability and safety profiles of hypolipidemic drugs are class-specific and can influence medication adherence and selection.

Common Side Effects

Statins are commonly associated with muscle-related symptoms, ranging from benign myalgias (5-10% of patients) to, more rarely, myositis. Other common effects include headache, gastrointestinal disturbances (dyspepsia, diarrhea, constipation), and elevated liver transaminases. Ezetimibe is generally well-tolerated, with side effects like diarrhea, abdominal pain, and nasopharyngitis being infrequent. Fibrates commonly cause gastrointestinal upset (dyspepsia, abdominal pain), rash, and a increased risk of cholelithiasis due to increased cholesterol secretion into bile.

Bile acid sequestrants frequently cause gastrointestinal effects such as constipation, bloating, and flatulence; they can also impair the absorption of fat-soluble vitamins (A, D, E, K). PCSK9 monoclonal antibodies most commonly cause injection site reactions (erythema, pain, bruising). Niacin is notorious for causing intense cutaneous flushing and pruritus, which is prostaglandin-mediated and often diminishes with continued use. It also commonly causes gastrointestinal irritation and can induce hyperuricemia and hyperglycemia.

Serious/Rare Adverse Reactions

The most serious adverse effect of statins is rhabdomyolysis, a life-threatening condition characterized by severe muscle breakdown, myoglobinuria, and acute kidney injury. The risk is dose-dependent and increased by drug interactions, particularly with CYP3A4 inhibitors. Hepatotoxicity, marked by a marked elevation in transaminases, is a rare but serious concern. Statin therapy has been associated with a small increased risk of new-onset diabetes mellitus, particularly in predisposed individuals.

Fibrates increase the risk of myopathy and rhabdomyolysis, especially when combined with statins, with gemfibrozil posing a greater risk than fenofibrate due to its pharmacokinetic interaction. They can cause reversible elevations in serum creatinine without necessarily indicating true kidney injury. Niacin can cause fulminant hepatotoxicity, particularly with sustained-release formulations, and can precipitate gout attacks. Lomitapide, used for homozygous familial hypercholesterolemia, carries a risk of hepatotoxicity and severe gastrointestinal malabsorption.

Black Box Warnings

Several hypolipidemic agents carry black box warnings, the strongest safety alert from regulatory agencies. Simvastatin carries a warning for myopathy/rhabdomyolysis, particularly at the 80 mg dose, which is no longer recommended. The warning also highlights the danger of concomitant use with certain potent CYP3A4 inhibitors (e.g., itraconazole, cyclosporine, gemfibrozil). Lomitapide has a black box warning for the risk of hepatotoxicity, requiring regular liver function test monitoring. Niacin extended-release formulations warn about severe liver toxicity and should not be substituted for equivalent doses of immediate-release niacin.

Drug Interactions

Given the chronic use of hypolipidemic drugs and their common metabolism pathways, the potential for clinically significant drug interactions is substantial.

Major Drug-Drug Interactions

Statins and CYP450 Inhibitors: Concomitant use of statins metabolized by CYP3A4 (simvastatin, lovastatin, atorvastatin) with potent inhibitors of this enzyme (e.g., macrolide antibiotics, azole antifungals, protease inhibitors, cyclosporine, amiodarone) dramatically increases statin exposure and the risk of myotoxicity. Similar concerns exist for fluvastatin with CYP2C9 inhibitors (e.g., fluconazole).

Statins and Gemfibrozil: Gemfibrozil inhibits the glucuronidation of most statins, markedly increasing their plasma concentrations and the risk of rhabdomyolysis. This combination is generally contraindicated. Fenofibrate has a lower interaction potential and is the preferred fibrate for combination therapy with a statin.

Bile Acid Sequestrants and Other Drugs: These resins can bind and impair the absorption of numerous oral medications, including warfarin, digoxin, thyroxine, and certain antibiotics and antifungals. Other drugs should be administered at least 1 hour before or 4-6 hours after the resin.

Niacin and Statins: The combination may increase the risk of myopathy. Ezetimibe has a low interaction profile but concentrations may be increased by fibrates. PCSK9 inhibitors, due to their non-enzymatic clearance, have minimal drug interaction potential.

Contraindications

Absolute contraindications are specific to each class. Statins are contraindicated in active liver disease or unexplained persistent elevations in serum transaminases, during pregnancy and lactation, and in patients with a history of hypersensitivity. Concomitant use of potent CYP3A4 inhibitors with simvastatin or lovastatin is contraindicated. Fibrates are contraindicated in patients with severe renal or hepatic dysfunction, pre-existing gallbladder disease, and in those with a history of hypersensitivity. Niacin is contraindicated in active peptic ulcer disease, significant hepatic impairment, and arterial hemorrhage. Bile acid sequestrants are contraindicated in complete biliary obstruction and in individuals with hypertriglyceridemia-induced pancreatitis.

Special Considerations

The use of hypolipidemic drugs requires careful adjustment and monitoring in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or safety concerns.

Use in Pregnancy and Lactation

Cholesterol and its products are essential for fetal development, including synthesis of cell membranes and steroid hormones. Therefore, most hypolipidemic drugs are contraindicated during pregnancy. Statins are classified as Pregnancy Category X due to potential teratogenic effects observed in animal studies. Fibrates, ezetimibe, and niacin are also generally avoided. Bile acid sequestrants, which are not systemically absorbed, may be considered in pregnant women with severe hypercholesterolemia, though they can interfere with vitamin absorption. All lipid-lowering drugs should be discontinued prior to conception and during breastfeeding, as their presence in breast milk is either confirmed or cannot be ruled out.

Pediatric and Geriatric Considerations

In pediatric patients with familial hypercholesterolemia, statins (e.g., atorvastatin, rosuvastatin) are approved for use in children as young as 8-10 years. Dosing is weight-based and initiated at the lowest recommended dose. Long-term safety data in children are still accumulating. In geriatric patients, age-related declines in renal and hepatic function necessitate caution. Statin doses may need to be reduced, particularly for agents with significant renal excretion (pravastatin, rosuvastatin). The increased prevalence of polypharmacy in the elderly heightens the risk of drug interactions. The benefits of therapy for primary prevention in older adults (e.g., >75 years) require individual assessment of life expectancy and comorbidities.

Renal and Hepatic Impairment

Renal Impairment: Statin pharmacokinetics can be altered in renal disease. Pravastatin and rosuvastatin require dose adjustment in severe chronic kidney disease (CKD). Atorvastatin and fluvastatin may require less adjustment. Fibrates are contraindicated in severe renal impairment due to an increased risk of myotoxicity and renal excretion; fenofibrate dose must be reduced in moderate CKD. Bile acid sequestrants are safe but may exacerbate constipation. Ezetimibe can be used without dose adjustment. PCSK9 inhibitors do not require renal dose adjustment.

Hepatic Impairment: As the liver is the primary site of action and metabolism for most lipid-lowering drugs, hepatic impairment warrants extreme caution. Statins are contraindicated in active liver disease or unexplained transaminase elevations. Fibrates should be avoided. Niacin is contraindicated. Ezetimibe may be used with caution. Bile acid sequestrants are not contraindicated but may be poorly tolerated. The effects of hepatic impairment on monoclonal antibody clearance are not well characterized, but they are generally considered safer alternatives in patients with stable chronic liver disease where LDL-C lowering is critical.

Summary/Key Points

• Hypolipidemic drugs are essential for reducing ASCVD risk by modifying plasma lipoprotein concentrations through diverse mechanisms targeting synthesis, absorption, and catabolism.
• Statins, as HMG-CoA reductase inhibitors, are first-line therapy for most patients, primarily upregulating hepatic LDL receptor activity to lower LDL-C and providing proven cardiovascular benefits.
• Adjunctive agents like ezetimibe (cholesterol absorption inhibitor) and PCSK9 inhibitors (monoclonal antibodies or siRNA) provide potent additional LDL-C lowering for high-risk patients or those who are statin-intolerant.
• Fibrates (PPAR-α agonists) and prescription omega-3 fatty acids (specifically icosapent ethyl) are first-line for managing severe hypertriglyceridemia to prevent pancreatitis, with icosapent ethyl also reducing cardiovascular events in high-risk patients on statins.
• Pharmacokinetic properties, particularly metabolism via CYP450 enzymes for statins, dictate major drug interaction risks, notably with CYP inhibitors and gemfibrozil, which can precipitate severe myotoxicity.
• Adverse effect profiles are class-specific: statins are associated with myalgia and rare rhabdomyolysis; fibrates with GI upset and increased creatinine; niacin with flushing and hepatotoxicity; bile acid sequestrants with GI effects and drug binding.
• Special population management is critical: most agents are contraindicated in pregnancy; renal/hepatic impairment requires dose adjustment or avoidance; and polypharmacy in the elderly increases interaction risk.

Clinical Pearls

• The choice of agent should be guided by the predominant lipid abnormality (elevated LDL-C vs. triglycerides), the patient’s absolute cardiovascular risk, and tolerability.
• For statin-associated muscle symptoms, strategies include a trial of de-challenge and re-challenge, switching to a different statin (e.g., a hydrophilic agent), or employing alternate-day dosing of a long-acting statin before declaring statin intolerance.
• When combining a fibrate with a statin, fenofibrate is preferred over gemfibrozil due to a lower risk of pharmacokinetic interaction and myopathy.
• Monitoring therapy involves checking a fasting lipid panel 4-12 weeks after initiation or dose change, and periodic monitoring of liver enzymes (AST/ALT) for patients on statins, fibrates, or niacin.
• For patients unable to achieve LDL-C goals on maximally tolerated oral therapy, PCSK9 inhibitors offer a highly effective, well-tolerated, though costly, injectable option with proven cardiovascular outcomes benefit.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.